Erasmus Jesse H, Rossi Shannan L, Weaver Scott C
Institute for Human Infections and Immunity.
Institute for Translational Science.
J Infect Dis. 2016 Dec 15;214(suppl 5):S488-S496. doi: 10.1093/infdis/jiw271.
Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.
基孔肯雅热是一种由蚊媒传播的基孔肯雅病毒（CHIKV）引起的急性且常为慢性的关节疼痛疾病，自2004年以来再度出现，导致数百万病例。由于CHIKV的抗原多样性有限且已知不会再次感染，一种疫苗可用于预防疾病并减少疫情传播期间的人际传播。在此，我们回顾自20世纪70年代以来为CHIKV开发的众多有前景的疫苗平台和候选疫苗，包括几种处于临床前后期或临床开发阶段的疫苗。我们讨论了每种疫苗的优缺点，以及将疫苗推向市场所面临的商业和监管挑战。
